MEK1/2 blockade by AZD6244 (ARRY-142886) inhibits tumor growth and progression in an orthotopic human lung adenocarcinoma model with enhanced efficacy when combined with cediranib

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Takahashi, O, Komaki, R, Smith, P, Ryan, A, Jurgensmeier, J, Welsh, J, Jacoby, J, Hosho, K, Korshunova, M, Erez, B, Herbst, R, O'Reilly, MS
Formáid:	Journal article
Foilsithe / Cruthaithe:	2009

DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma
de réir: Gupta, A, et al.
Foilsithe / Cruthaithe: (2013)

AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study
de réir: Dummer, R, et al.
Foilsithe / Cruthaithe: (2008)

Author Correction: Targeting inhibition of extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) suppresses growth and angiogenesis of gastric cancer
de réir: Jin-Hang Gao, et al.
Foilsithe / Cruthaithe: (2022-03-01)

Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.
de réir: Takahashi, O, et al.
Foilsithe / Cruthaithe: (2012)

Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis
de réir: Takahashi, O, et al.
Foilsithe / Cruthaithe: (2012)

Targeted Therapy Against All Three VEGF Receptors by Cediranib Enhances the Antitumor and Anti-metastatic Effects of Paclitaxel and Radiation in an Orthotopic Human Lung Cancer Model
de réir: Takahashi, O, et al.
Foilsithe / Cruthaithe: (2010)

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
de réir: Leijen, S, et al.
Foilsithe / Cruthaithe: (2011)

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
de réir: Leijen, S, et al.
Foilsithe / Cruthaithe: (2011)

Targeting ERK1/2 activation and proliferation in human primary schwannoma cells with MEK1/2 inhibitor AZD6244
de réir: Sylwia Ammoun, et al.
Foilsithe / Cruthaithe: (2010-01-01)

Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines.
de réir: Morelli, M, et al.
Foilsithe / Cruthaithe: (2009)

Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinoma.
de réir: Medinger, M, et al.
Foilsithe / Cruthaithe: (2009)

Resistance to Selumetinib (AZD6244) in Colorectal Cancer Cell Lines is Mediated by p70S6K and RPS6 Activation
de réir: Silvina Grasso, et al.
Foilsithe / Cruthaithe: (2014-10-01)

Evaluation of novel combined carbogen USPIO (CUSPIO) imaging biomarkers in assessing the antiangiogenic effects of cediranib (AZD2171) in rat C6 gliomas
de réir: Burrell, J, et al.
Foilsithe / Cruthaithe: (2012)

Evaluation of novel combined carbogen USPIO (CUSPIO) imaging biomarkers in assessing the antiangiogenic effects of cediranib (AZD2171) in rat C6 gliomas.
de réir: Burrell, J, et al.
Foilsithe / Cruthaithe: (2012)

The effect of food on the single dose pharmacokinetics of cediranib
de réir: Jayson, G, et al.
Foilsithe / Cruthaithe: (2008)

Multi-center randomized phase II study comparing cediranib plus gefitinib with cediranib plus placebo in subjects with recurrent/progressive glioblastoma
de réir: Brown, N, et al.
Foilsithe / Cruthaithe: (2016)

Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma.
de réir: Nicholas Brown, et al.
Foilsithe / Cruthaithe: (2016-01-01)

Comparisons of the Efficacy of a Jak1/2 Inhibitor (AZD1480) with a VEGF Signaling Inhibitor (Cediranib) and Sham Treatments in Mouse Tumors Using DCE-MRI, DW-MRI, and Histology
de réir: Mary E. Loveless, et al.
Foilsithe / Cruthaithe: (2012-01-01)

Computer interfacing with radial line slot arry (RLSA) antenna measurement /
de réir: 254621 Chin, Wen Sing
Foilsithe / Cruthaithe: (1999)

Monitoring and quantification of rural urbanisation: Case of Arris and Theniet Elabed, Algeria
de réir: Soto Sabrina, et al.
Foilsithe / Cruthaithe: (2024-01-01)

In search of an architectural genome of traditional houses: Case of the habitat of the Dechras of Arris
de réir: Aksas Samiha, et al.
Foilsithe / Cruthaithe: (2023-01-01)

Fingerprint-fingervein multimodal biometric authentication system on field programmable gate arry /
de réir: Chong, Yew Hoe, 1992-, et al.
Foilsithe / Cruthaithe: (2015)

Dual axis rotation solar irradiance tracking system for photovoltaic arry [electronic resource] /
de réir: Thanikaikumaran R. Kuppusamy, 1987-, author 646957, et al.
Foilsithe / Cruthaithe: (2017)

The phenomenon of repetition according to Abu Al-Ala’ Al-Ma’arri in “The Chapters and Ends”
de réir: زهره قرباني مادواني
Foilsithe / Cruthaithe: (2018-02-01)

Changes in perfusion and permeability in glioblastoma model induced by the anti-angiogenic agents cediranib and thalidomide
de réir: Jérôme Conq, et al.
Foilsithe / Cruthaithe: (2024-08-01)

Synergistic Antivascular and Antitumor Efficacy with Combined Cediranib and SC6889 in Intracranial Mouse Glioma.
de réir: Merryl R Lobo, et al.
Foilsithe / Cruthaithe: (2015-01-01)

Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy
de réir: Jianling Bi, et al.
Foilsithe / Cruthaithe: (2021-07-01)

Fingerprint-fingervein multimodal biometric authentication system on field programmable gate arry [electronic resource] /
de réir: Chong, Yew Hoe, 1992-, et al.
Foilsithe / Cruthaithe: (2015)

An optical wavelength multi/demultiplexing (DWDM/CWDM) based arry waveguide grating (AWG) technique /
de réir: 333366 Ismahayati Adam, et al.
Foilsithe / Cruthaithe: (2008)

KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells
de réir: Woessner Richard, et al.
Foilsithe / Cruthaithe: (2009-07-01)

Combined efficacy of cediranib and quinacrine in glioma is enhanced by hypoxia and causally linked to autophagic vacuole accumulation.
de réir: Merryl R Lobo, et al.
Foilsithe / Cruthaithe: (2014-01-01)

Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
de réir: Sarah J. Welsh, et al.
Foilsithe / Cruthaithe: (2015-03-01)

<b>Peroxidase activity in <em>Spondias dulcis</em></b> - 10.4025/actascitechnol.v32i4.6244
de réir: Dayse Pereira Barbosa Souza, et al.
Foilsithe / Cruthaithe: (2010-12-01)

Normal Computed Tomography and Radiographic Study of the Nasal Cavity and Paranasal Sinuses in Shal Sheep (Ovis arries)
de réir: Alireza Vajhi, et al.
Foilsithe / Cruthaithe: (2023-10-01)

Abu Ala El-Ma'arri's Opinion on Rajaz | موقف أبي العلاء المعري من الرجز
de réir: Ali Hasan Bahar
Foilsithe / Cruthaithe: (2009-12-01)

Pulmonary tumor thrombotic microangiopathy and pulmonary veno-occlusive disease in a woman with cervical cancer treated with cediranib and durvalumab
de réir: Dante A. Suffredini, et al.
Foilsithe / Cruthaithe: (2018-07-01)

An optical wavelength multi/demultiplexing (DWDM/CWDM) based arry waveguide grating (AWG) technique [Electronic Resource] /
de réir: 333366 Ismahayati Adam, et al.
Foilsithe / Cruthaithe: (2008)

ŞAiR EBU'L- ALA EL-MA'ARRi, HAYATI, ESERLERi VE EDEBi ANLAYlŞI
de réir: Mustafa Kırkız
Foilsithe / Cruthaithe: (2011-06-01)

Sastra Arab dan Disabilitas: Pendekatan Ekspresif terhadap Puisi “al-Marsiyyah” Karya al-Ma’arri
de réir: Tatik Mariyatut Tasnimah
Foilsithe / Cruthaithe: (2019-06-01)

Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation
de réir: Batchelor, Tracy T., et al.
Foilsithe / Cruthaithe: (2014)

MEK1/2 blockade by AZD6244 (ARRY-142886) inhibits tumor growth and progression in an orthotopic human lung adenocarcinoma model with enhanced efficacy when combined with cediranib

Míreanna comhchosúla

Míreanna comhchosúla